James (Jay) Bradner, M.D., has been President of the Novartis Institutes for BioMedical Research (NIBR) since 2016. He is a member of the Executive Committee of Novartis.
From 2005 to 2015, Dr. Bradner served as an attending physician in stem cell transplantation within the Department of Medical Oncology at the Dana-Farber Cancer Institute in the United States. He was an associate professor within the Department of Medicine at Harvard Medical School in the US from 2014 to 2016, and an assistant professor there from 2010 to 2014. He has co-founded five biotechnology companies and has co-authored more than 200 scientific publications and 30 US patent applications.
Dr. Bradner received his doctor of medicine from the University of Chicago Pritzker School of Medicine in the US, and his bachelor’s degree in biochemistry from Harvard University. He completed his residency in medicine at Brigham and Women's Hospital, his fellowship in medical oncology and hematology at the Dana-Farber Cancer Institute, and his postdoctoral training in chemistry and chemical biology at Harvard University. He has received many honorific awards and was elected into the American Society for Clinical Investigation in 2011 and the Alpha Omega Alpha Honor Medical Society in 2013. He serves as Chairman of the Genomics Institute of the Novartis Research Foundation in the US.